Companies · Biotech
WALTHAM · Biotech · refined from filed group “Other Health Care” · https://www.perkinelmer.com/
Diligence memoA one-page analyst read on Perkinelmer Inc — recommendation, valuation, rhythm, risks.→Perkinelmer Inc has raised $2.2B over 1 round; too few niche peers to rank its valuation yet.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Perkinelmer Inc is one of 233 Biotech companies tracked from WALTHAM. By capital raised it ranks among the largest (ahead of 100% of sector peers), and among the largest by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%
operates a technology-led product inferred from public copy
Grounded in: “You are a venture analyst”
PerkinElmer | Science with Purpose
Together with scientists and operators worldwide, we empower progress by providing trusted insights and services that accelerate work and amplify impact for a healthier, safer, and more sustainable world. Customers served in 168 countries (direct and through distributors). Manufacturing presence in North-America, Europe and APAC, incl. China. We believe great ideas can come from anywhere – because our customers rely on the ingenuity, creativity, and passion of our people. We’re on a mission to transform our world. Will you join us? Project Farma, PerkinElmer’s patient-focused life sciences consulting firm dedicated to accelerating manufacturing for life-changing therapies, today announced a partnership with Oracle Primavera Cloud (OPC) to enhance its project controls and capital program delivery capabilities for pharmaceutical and biotech organizations. Project Farma, PerkinElmer’s patient-focused life sciences consulting firm dedicated to accelerating manufacturing for life-changing therapies, today announced its Gold Tier Certified Partner status with Valkit.ai, an AI-powered digital validation platform that streamlines compliance and quality processes for life sciences organizat
Trades publicly as PerkinElmer.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A, Series B, Series C, Series D+ — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 14%.
Round size and date are reported; the stage label is inferred from round size (latest is Growth/Late — a round over $400M). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 233 companies in Biotech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 100% of sector peers (real $). Modeled value above 100% of peers (estimate).
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Growth/Late | $2.2B | 2021-09-17 | $22.0B | $65.2B | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Joel S Goldberg | — | 1 other | 2021-09 |
| Alexis P. Michas | — | — | 2021-09 |
| Andrew R. Okun | — | — | 2021-09 |
| Daniel R. Tereau | — | — | 2021-09 |
| Frank P. Witney | — | — | 2021-09 |
| James M. Mock | — | — | 2021-09 |
| Michel P. Vounatsos | — | — | 2021-09 |
| Miriame R. Victor | — | — | 2021-09 |
| Pascale P. Witz | — | — | 2021-09 |
| Peter R. Barrett | — | — | 2021-09 |
| Prahlad Singh | — | — | 2021-09 |
| Samuel R. Chapin | — | — | 2021-09 |
| Sylvie R. Gregoire | — | — | 2021-09 |
| Tajinder R. Vohra | — | — | 2021-09 |
Perkinelmer Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Discovered from perkinelmer — the partnerships, launches, hiring and press it publishes about itself. Evidence the company is alive and what it is doing now, not financial data.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Nautilus Biotechnology, Inc. | Biotech | Series D+ | $303.3M | $6.0B | same sector |
| Octave Bioscience Inc | Biotech | Series B | $105.8M | $169.3M | same sector |
| TetraScience, Inc. | Biotech | Series C | $66.0M | $72.1M | same sector |
| Watchmaker Genomics, Inc. | Biotech | Series B | $48.3M | $712.8M | same sector |
| 54Gene, Inc. | Biotech | Series B | $48.3M | $598.4M | same sector |
| Trace Genomics, Inc. | Biotech | Series B | $45.3M | $184.6M | same sector |
| AgNovos Bioscience, Inc. | Biotech | Series B | $44.8M | $119.7M | same sector |
| Lygos, Inc. | Biotech | Series B | $41.7M | $432.7M | same sector |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Maven Bio The AI Platform for Life Sciences Intelligence | Biotech | — | — | 79% |
| Percipient.ai Inc. | AI / ML | Series C | $199.5M | 78% |
| Perlara Perlara: building the YC for rare disease parents | Biotech | — | — | 77% |
| Bio-AI Health Inc. | Biotechnology | Seed | $2.8M | 77% |
| 64x Bio Enabling next generation medicines. A comprehensive platform and… | Biotech / Pharma | — | — | 77% |
| BioStack Platforms Real world training envs for healthcare AI models | Pharma | — | — | 76% |
| PDX Pharmaceuticals, Inc. | Biotechnology | Seed | $68.8M | 76% |
| Convexia The world's first AI-maximalist pharma company | Biotech | — | — | 76% |
See where Perkinelmer Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Perkinelmer Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.